HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Efficacy of sunitinib in Turkish patients with gastrointestinal stromal tumors; retrospective multicenter experience.

AbstractBACKGROUND/AIMS:
Sunitinib is a multi-targeted thyrosine kinase receptor inhibitor used in patients with advanced gastrointestinal stromal tumours (GISTs). We evaluated the efficacy and tolerability of sunitinib therapy in Turkish patients with GISTs.
METHODOLOGY:
Between January 2001 and April 2012, 57 patients who had progressive disease or experienced unacceptable toxicity during imatinib treatment from multiple centers were investigated retrospectively.
RESULTS:
Thirty-three patients were male and 24 were female. The median age was 55 years (range; 16-84 years). Thirty-eight of the patients received imatinib for longer than 12 months, 13 patients received for 6-12 months, and 6 patients received for less than six months. The clinical benefit of sunitinib was 73.7%. Treatment-related adverse events were reported in 78% of the patients. Adverse events were generally mild to moderate in intensity. The median progression free survival (PFS) and overall survival (OS) of the patients that received sunitinib were 10.8 months and 23.9 months, respectively. The time of imatinib usage and response to sunitinib were independent prognostic factors for PFS and OS. Also, tumor size was an independent prognostic factor for PFS.
CONCLUSIONS:
Sunitinib is an effective treatment in Turkish patients with GISTs, with a clinical benefit of 73.7% and shows an acceptable tolerability.
AuthorsUmut Kefeli, Suleyman Buyuberber, Murat Akyol, Ramazan Yildiz, Muhammed Ali Kaplan, Aydin Ciltas, Alper Sevinc, Halit Karaca, Mesut Seker, Nuriye Ozdemir, Ahmet Alacacioglu, Ugur Coskun, Abdurrahman Isikdogan, Faysal Dane, Mahmut Gumus, Metin Ozkan, Ali Suner, Mustafa Oktay Tarhan, Mustafa Benekli
JournalHepato-gastroenterology (Hepatogastroenterology) Vol. 60 Issue 124 Pg. 647-52 (Jun 2013) ISSN: 0172-6390 [Print] Greece
PMID23165189 (Publication Type: Journal Article, Multicenter Study)
Chemical References
  • Antineoplastic Agents
  • Indoles
  • Pyrroles
  • Sunitinib
Topics
  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Agents (adverse effects, therapeutic use)
  • Female
  • Gastrointestinal Neoplasms (drug therapy, epidemiology, surgery)
  • Gastrointestinal Stromal Tumors (drug therapy, epidemiology, surgery)
  • Humans
  • Indoles (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Pyrroles (adverse effects, therapeutic use)
  • Retrospective Studies
  • Sunitinib
  • Treatment Outcome
  • Turkey (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: